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Clinical antimicrobial susceptibility breakpoints are
used to predict the clinical outcome of antimicrobial treat-
ment. In contrast, microbiologic breakpoints are used to
identify isolates that may be categorized as susceptible
when applying clinical breakpoints but harbor resistance
mechanisms that result in their reduced susceptibility to the
agent being tested. Currently, the National Committee for
Clinical Laboratory Standards (NCCLS) guidelines utilize
clinical breakpoints to characterize the activity of the fluoro-
quinolones against Streptococcus pneumoniae. To deter-
mine whether levofloxacin breakpoints can identify isolates
that harbor recognized resistance mechanisms, we exam-
ined 115 S. pneumoniae isolates with a levofloxacin MIC of
>2 µg/mL for first-step parC mutations. A total of 48 (59%)
of 82 isolates with a levofloxacin MIC of 2 µg/mL, a level
considered susceptible by NCCLS criteria, had a first-step
mutation in parC. Whether surveillance programs that use
levofloxacin data can effectively detect emerging resist-
ance and whether fluoroquinolones can effectively treat
infections caused by such isolates should be evaluated.
T
he emergence of Streptococcus pneumoniae resistance
to β-lactam and macrolide antimicrobial agents has led
to recommendations that fluoroquinolones with increased
activity against S. pneumoniae, such as levofloxacin, mox-
ifloxacin, and gatifloxacin, be used to treat patients at risk
for infection caused by such multidrug-resistant strains
(1–6). Fluoroquinolone resistance in S. pneumoniae is pri-
marily due to mutations in the genes encoding the target
topoisomerase enzymes, namely parC, which encodes the
A subunit of DNA topoisomerase IV, and gyrA, which
encodes the A subunit of DNA gyrase (7). Mutations in
parE and gyrB have been reported, but to a lesser extent
(8–10). Most pneumococcal isolates with reduced suscep-
tibilities to fluoroquinolones have amino acid substitutions
in either ParC alone or ParC and GyrA(11–14). Resistance
can also be mediated by active efflux (15), although the
role of efflux in contributing to resistance by the newer
fluoroquinolones is unclear (16).
The MIC of an antimicrobial agent is a value that has
been used to determine breakpoints that predict the proba-
bility of clinical success, detect resistant populations, or
both (17). Clinical breakpoints are dependent on the
antimicrobial activity and pharmacology of the drug; such
breakpoints are ascertained with the goals of eradicating
the infection and ultimately achieving clinical success with
the antimicrobial agent. In contrast, microbiologic break-
points are established to identify isolates that may be cate-
gorized as susceptible when applying clinical breakpoints
but harbor resistance mechanisms that result in their
reduced susceptibility to the agent being tested. These
microbiologic breakpoints are therefore useful in monitor-
ing the emergence of resistance. The current National
Committee for Clinical Laboratory Standards (NCCLS)
guidelines make no distinction between these two interpre-
tations of MIC, with clinical breakpoints used to character-
ize most antimicrobial agents, including the fluoro-
quinolones.
Levofloxacin has been used as a surrogate marker to
predict fluoroquinolone susceptibility in clinical laborato-
ries and surveillance studies (18). To establish whether
current levofloxacin breakpoints are also able to function
as microbiologic breakpoints, we determined the percent-
age of S. pneumoniae isolates with first-step parC muta-
tions that would go undetected by using the current
NCCLS breakpoints for levofloxacin (19). 
Materials and Methods
Atotal of 6,076 clinical isolates of S. pneumoniae were
collected as part of a 1993–1998 surveillance program
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moniae by standard methods. The isolates were frozen at
–70°C, thawed, subcultured onto blood agar, and incubated
at 37°C in 5% CO2 for 24 h twice before testing. In vitro
susceptibility testing was performed by broth microdilu-
tion, according to NCCLS guidelines (20,21).
Susceptibility interpretive criteria used were those pub-
lished in the NCCLS M100-S12 document (19). The non-
susceptible category was defined as those isolates with
MICs of fluoroquinolines in the intermediate and resistant
category. The parC gene of 115 isolates with a levofloxacin
MIC >2 µg/mL(82 = MIC 2 µg/mL; 8 = MIC 4 µg/mL; 10
= MIC 8 µg/mL; and 15 = MIC ≥16 µg/mL) was amplified
by polymerase chain reaction (PCR),  and the nucleotide
sequence determined as previously described (9). All iso-
lates (n=33) with a levofloxacin MIC of ≥4 µg/mL, and a
random sample of 29 isolates with a levofloxacin MIC of 2
µg/mL were examined for gyrA mutations. For compara-
tive purposes, the parC  gene of 14 isolates with a
ciprofloxacin MIC of 2 µg/mL, regardless of their lev-
ofloxacin MIC, was amplified and sequenced. Although
numerous single mutational events occur in parC, the focus
of this investigation was on amino acid substitutions for
Ser-79 or Asp-83, because previous studies have consis-
tently demonstrated that mutations at either of these posi-
tions are associated with decreased susceptibility (9,14).
Crude cell lysates were used as DNA templates for
PCR. After overnight growth on Columbia nutrient agar
and supplemented with 5% sheep blood, a loopful of
growth was suspended in 100 µL of lysis buffer (100 mM
NaCl, 10 mM Tris-HCl [pH 8.3], 1 mM EDTA, 1% Triton
X-100) and boiled for 10 min. Ten microliters of the super-
natant was used as the template in a 50-µL reaction vol-
ume. The quinolone-resistance–determining regions of
parC and gyrA were amplified by PCR. Primers used were
based on published sequences (7,8), and amplification
products were purified with either the QIAquick PCR
purification kit (Qiagen Inc., Mississauga, Ontario,
Canada) or the Concert Rapid PCR purification kit (Life
Technologies, Burlington, Ontario, Canada).
DNAsequencing was performed by ABI prism Big Dye
terminator cycle sequencing with the ABI 377 automated
sequencer (PE Applied Biosystems, Mississauga, Ontario,
Canada). Nucleotide and amino acid sequence compar-
isons were performed by the multiple-alignment sequence
function of Vector NTI Suite software (InforMax Inc.,
Bethesda, MD). The GenBank accession numbers for the
wild-type sequences used for comparison purposes were
Z67739 for parC and parE (22), AB010387 for gyrA, and
Z67740 for gyrB (23).
Isolates were examined for active efflux by agar dilu-
tion on Mueller-Hinton agarcontaining 5% sheep blood in
the presence of ciprofloxacin with or without 10 mg/mLof
reserpine (Sigma Chemical Co., St. Louis, MO) (24).
Strains for which a fourfoldor greater decrease in the MIC
of ciprofloxacin existed in the presence of reserpine were
considered in this study to be positive for reserpine-inhib-
ited efflux. S. pneumoniae strain P121/1N27 and clinical
isolate BSP 823 were used as quality control strains, the
latter of which demonstrated a 16-fold decrease in the
ciprofloxacin MIC in the presence of reserpine (9).
Results
Of the 115 S. pneumoniae isolates with a levofloxacin
MIC >2 µg/mL, 78 (69%) had an amino acid substitution
in ParC (Ser-79 or Asp-83) (Table 1). Mutations in gyrA
were not found in any of the randomly selected isolates
with a levofloxacin MIC of 2 µg/mL, but were present in
three (38%) of eight isolates with a levofloxacin MIC of 4
µg/mL and in all isolates with a levofloxacin MIC ≥ 8
µg/mL (Table 2). The specific ParC amino acid substitu-
tions of the isolates and their corresponding levofloxacin
MICs are shown in Table 1. The most common substitution
was Ser-79 to Phe, accounting for 60% of all observed
amino acid substitutions. The prevalence of first-step ParC
amino acid substitutions among all strains according to
their levofloxacin and ciprofloxacin MICs is shown in
Table 3. Using the current MIC interpretive standards for
levofloxacin, 48 (59%) of 82 of isolates with a first-step
mutation fall in the susceptibility category of levofloxacin
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Table 1. ParC amino acid substitutions found in 115 Streptococcus pneumoniae isolates with levofloxacin MICs >2 µg/mL and 
corresponding levofloxacin MICs 
No. isolates inhibited by levofloxacin MIC (µg/mL) of  ParC amino acid 
substitution  2  4  8  16  ≥32  Total no. of strains 
Ser79→Phe  28  4  3  9  3  47 
Ser79→Tyr  7  1  3  2  1  14 
Ser79→Ala  1  0  0  0  0  1 
Asp83→Asn  7  0  3  0  0  10 
Asp83→Gly  1  0  0  0  0  1 
Asp83→Tyr  3  0  0a  0  0  3 
Asp83→Val  1  0  0  0  0  1 
Asp83→Ala  0  0  1  0  0  1 
No. isolates/total with 
amino acid substitutions 
48/82 (59%)  5/8
a (63%)  10/10  11/11  4/4  78/115 (69%) 
aOne isolate with no ParC amino acid substitution found to have active efflux; two isolates had ParC amino acid substitutions at sites other than Ser79 or Asp83. (MIC<4 µg/mL). In comparison, 4 (29%) of 14 randomly
chosen isolates with a ciprofloxacin MIC of 2 µg/mL har-
bored a first-step mutation. 
Thirty-three isolates were nonsusceptible to lev-
ofloxacin (MIC>4 µg/mL); for 25, which harbored both
ParC and GyrA amino acid substitutions, the levofloxacin
MIC was ≥8 µg/mL (Table 3). For eight isolates, the lev-
ofloxacin MIC was 4 µg/mL; three (38%) of those isolates
had a substitution in GyrA (Ser-81-Phe) as well as a sub-
stitution in ParC (Ser-79-Phe, Asp-78-Asn and Ala-115-
Pro) (Table 4). In addition, two of the eight (25%) isolates
had no substitution in GyrA, but were considered positive
for reserpine-inhibited efflux, while three isolates had a
Ser-79-Phe amino acid substitution in ParC. No mutations
were found in either parE or gyrB in the isolates with a
levofloxacin MIC of 4 µg/mL.
Discussion 
Before the development of fluoroquinolones such as
levofloxacin, ofloxacin was used to determine trends of
pneumococcal fluoroquinolone resistance in the United
States (25). By using this system, an increase of ofloxacin-
nonsusceptible isolates from 2.6% in 1995 to 3.8% in 1997
was reported. However, the significance of such an
increase was questioned, since ofloxacin-resistant strains
could be observed with only a single topoisomerase muta-
tion, whereas for fluoroquinolones such as levofloxacin,
multiple mutations are required for a strain to be classified
as resistant according to NCCLS breakpoints (25–27). As
a consequence, ofloxacin was replaced by levofloxacin in
1998 as a marker for fluoroquinolone nonsusceptibility,
and not surprisingly, given levofloxacin’s increased activi-
ty against S. pneumoniae, fluoroquinolone resistance rates
were only 0.2% in 1998 and 1999 (25). 
Since effective surveillance depends upon the ability to
detect the emergence of resistance, the prevalence of pneu-
mococci that harbor resistance mechanisms to the fluoro-
quinolones may not be accurately represented if surveil-
lance systems that rely on levofloxacin MIC data are used
(25,28–34). We found that 59% of isolates with a lev-
ofloxacin MIC of 2 µg/mL, a level considered susceptible
according to NCCLS criteria, had a first-step mutation in
parC. Similarly, Davies et al. (12) found that of 14 strains
for which levofloxacin MICs were 2 µg/mL, 10 (71%) had
a parC mutation. Therefore, if the goal of surveillance is to
detect emerging problems, then by extension, the detection
of first-step mutations is also important and the use of cur-
rent NCCLS breakpoints to estimate fluoroquinolone
resistance is clearly inadequate. Apart from DNAsequenc-
ing, currently no accurate test can reliably identify isolates
with first-step mutations (35). Although decreasing lev-
ofloxacin breakpoints has been proposed as a solution to
this problem, we found that 8 (25%) of 32 strains for which
the levofloxacin MIC was 1 µg/mL already had first-step
mutations (data not shown). Similarly, the replacement of
levofloxacin as a surveillance indicator by another fluoro-
quinolone has also been suggested. However, use of
ciprofloxacin does not fare significantly better, with 4
(29%) of 14 isolates in the susceptible category (MIC of 4
µg/mL to define nonsusceptible isolates) harboring first-
step mutations. 
In addition to causing an underestimation of the emer-
gence of fluoroquinolone resistance, the use of clinical
breakpoints has therapeutic implications, as supported by
recent reports of treatment failure when a fluoroquinolone
was used to treat an infection caused by a strain of pneu-
mococci with a first-step mutation (36,37). Clearly, a first-
step mutation is necessary for the development of subse-
quent mutations, the latter of which result in MICs that fall
within the nonsusceptible category. However, studies have
shown that upon acquisition of a first-step mutation, the
likelihood of developing a subsequent mutation is
enhanced in comparison to the development of the first-
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Table 2. Number of isolates with ParC and GyrA amino acid 
substitutions and their corresponding levofloxacin MICs 
No.  strains with amino acid substitutions in 
MIC (µg/mL)  ParC (%)  ParC and GyrA (%) 
2  48/82 (59)  0/29
a (0) 
4  5/8 (63)  3/8 (38) 
8  0/10 (0)  10/10 (100) 
≥16  0/15 (0)  15/15 (100) 
a29/82 isolates were randomly examined for GyrA mutations.  
Table 3. The prevalence of ParC amino acid substitutions 
among all strains according to their levofloxacin and 
ciprofloxacin MICs 
No. strains with ParC amino acid  
substitution at 79 or 83 
MIC (µg/mL)  Ciprofloxacin (%)  Levofloxacin (%) 
2  4/14 (29)  48/82 (59) 
4  24/37 (65)  5/8 (63)
 
8  11/12 (92)  10/10 (100) 
>8  22/22 (100)  15/15 (100) 
Total  62/87 (71)  78/115 (69) 
Table 4. Characterization of Streptococcus pneumoniae isolates 
with levofloxacin MIC 4 µg/mL
a 
Amino acid substitution 
Isolate 
no. 
In ParC  In GyrA 
Change in MIC 
with inhibition of 
efflux 
1  Ser79→Phe  None  8-fold 
2  Ser79→Phe  None  No effect 
3  Asp78→Asn  Ser81→Phe  No effect 
4  Ala115→Pro  Ser81→Phe  No effect 
5  Ser79→Phe  None  No effect 
6  Ser79→Phe  None  No effect 
7  None  None  4-fold 
8  Ser79→Phe  Ser81→Phe  No effect 
aparE and gyrB sequencing was performed on all isolates, but no mutations were 
found in the quinolone-resistance–determining region. step mutation itself (38–40). Studies are required to deter-
mine whether isolates with one or more mutations in genes
encoding ParC, GyrA, or both, can still be effectively treat-
ed with a fluoroquinolone when that fluoroquinolone is
found to be susceptible by using current clinical break-
points. Recognizing the presence of underlying mutations
may be especially important when using these agents to
treat patients with large biomass infections such as pneu-
mococcal pneumonia. 
Lastly, the acquisition of a second-step mutation
appears more likely than not to raise the MIC to >8 µg/mL
and not to 4 µg/mL as would be expected. Isolates with a
levofloxacin MIC of 4 µg/mLrepresented 0.1% of the total
number of isolates in our study, which is notable, consid-
ering that a levofloxacin MIC of 4 µg/mL is currently used
to define nonsusceptibility. Furthermore, these isolates
were for the most part either genotypically or phenotypi-
cally distinct from other isolates characterized (Table 4);
two had efflux mechanisms, one singly and the other con-
current with a ParC amino acid substitution, and two had
unusual substitutions in ParC (Asp78→Asn and
Ala115→Pro). The importance of this latter finding
remains to be determined.
In summary, levofloxacin susceptibility testing that
uses current MIC clinical breakpoints does not identify
most  S. pneumoniae isolates with only first-step parC
mutations. This finding may not only have implications for
the ability of surveillance programs to detect emerging
resistance, but therapeutic implications as well.
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